Biphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation | Zendy

Nahid Tabibzadeh | Zendy; Nathalie Chavarot | Zendy; Martin Flamant | Zendy; Emmanuelle VidalPetiot | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation

Author(s) -

Nahid Tabibzadeh,

Nathalie Chavarot,

Martin Flamant,

Emmanuelle VidalPetiot

Publication year - 2019

Publication title -

journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.451

H-Index - 279

eISSN - 1533-3450

pISSN - 1046-6673

DOI - 10.1681/asn.2019010079

Subject(s) - medicine , osteopenia , bone mineral , osteoporosis , kidney transplantation , transplantation , population , dialysis , kidney disease , randomized controlled trial , chronic kidney disease mineral and bone disorder , surgery , renal osteodystrophy , environmental health

We read with great interest “A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation” by Marques et al. [1][1] This study suggests that bisphosphonates are safe and probably beneficial in preventing the risk of fractures in kidney transplant

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research